10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2013 | |||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 13, 2014) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Income Statement [Abstract] | |||
| Revenues: | |||
| Net product sales | $ 1,425,839 | 858,093 | 44,686 |
| Sanofi collaboration revenue | 430,111 | 423,814 | 326,609 |
| Bayer HealthCare collaboration revenue | 220,289 | 70,099 | 43,072 |
| Technology licensing and other revenue | 28,506 | 26,471 | 31,457 |
| Total revenues | 2,104,745 | 1,378,477 | 445,824 |
| Expenses: | |||
| Research and development | 859,947 | 625,554 | 529,506 |
| Selling, general, and administrative | 329,415 | 210,755 | 117,261 |
| Cost of goods sold | 118,048 | 83,927 | 4,216 |
| Cost of collaboration manufacturing | 37,307 | 528 | 0 |
| Total expenses | 1,344,717 | 920,764 | 650,983 |
| Income (loss) from operations | 760,028 | 457,713 | (205,159) |
| Other income (expense): | |||
| Investment (expense) income | (231) | 2,012 | 3,549 |
| Interest expense | (46,437) | (45,304) | (21,282) |
| Total other income (expense) | (46,668) | (43,292) | (17,733) |
| Income (loss) before income taxes | 713,360 | 414,421 | (222,892) |
| Income tax (expense) benefit | (288,998) | 335,848 | 1,132 |
| Net income (loss) | 424,362 | 750,269 | (221,760) |
| Net income (loss) per share - basic | 4.33 | 7.92 | (2.45) |
| Net income (loss) per share - diluted | 3.81 | 6.75 | (2.45) |
| Weighted average shares outstanding - basic | 97,917 | 94,685 | 90,610 |
| Weighted average shares outstanding - diluted | 111,290 | 115,382 | 90,610 |
| Statements of Comprehensive Income (Loss) | |||
| Net income (loss) | 424,362 | 750,269 | (221,760) |
| Other comprehensive income (loss): | |||
| Unrealized (loss) gain on marketable securities, net of tax | (22) | 696 | 629 |
| Comprehensive income (loss) | 424,340 | 750,965 | (221,131) |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |